For US Healthcare Professionals Only
Order Now
NIOX® Customer Experience
1-866-275-6469, Option 2
Monday-Friday, 8AM-7PM ET

Publications & Whitepapers

Recent Noteworthy Publications

Clinical Studies

Anderson, WJ, Short, PM, Jabbal, S, Lipworth, BJ. Inhaled corticosteroid dose response in asthma.  Should we measure inflammation? Ann Allergy Asthma Immunol 2017, 118, 179e185.

Coumou H, Westerhof GA, de Nijs SB, et al. Predictors of accelerated decline in lung function in adult-onset asthma. Eur Respir J. 2018; 51: 1701785.

Hanania N, Massanari M, Jain N. Measurement of fractional exhaled nitric oxide in real-world clinical practice alters asthma treatment decisions. Ann Allergy Asthma Immunol. 2018;120: 414–418.

Karrasch S, Linde K, Rücker G, et al. Accuracy of FENO for diagnosing asthma: a systematic review. Thorax 2017; 72:109–116.

Morten M, Collison A, Murphy VE, et al. Managing Asthma in Pregnancy (MAP) trial: FeNO levels and childhood asthma. J Allergy Clin Immunol 2018; doi: 10.1016/j.jaci.2018.02.039.

Price D, Buhl R, Chan A, et al. Fractional exhaled nitric oxide as a predictor of response to inhaled corticosteroids in patients with non-specific respiratory symptoms and insignificant bronchodilator reversibility: a randomised controlled trial. Lancet Resp Med 2017; Published Online November 3, 2017. http://dx.doi.org/10.1016/S2213-2600(17)30424-1

Cost Effectiveness

Arnold RJ, Massanari M, Lee TA, Brooks E. A Review of the Utility and Cost Effectiveness of Monitoring Fractional Exhaled Nitric Oxide (FeNO) in Asthma Management. Manag Care. 2018 Jul;27(7):34-41.

Arnold RJG, Layton A, Massanari M. Cost impact of monitoring exhaled nitric oxide in asthma management. Allergy Asthma Proc. 2018 Aug 13. doi: 10.2500/aap.2018.39.4165. [Epub ahead of print]

Brooks EA, Massanari M. Cost-Effectiveness Analysis of Monitoring Fractional Exhaled Nitric Oxide (FeNO) in the Management of Asthma. Manag Care. 2018 Jul;27(7):42-48.

Evidence Reviews

Petsky HL, Cates CJ, Kew KM, Chang AB. Tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils): a systematic review and meta-analysis. Thorax. 2018 Jun 1. pii: thoraxjnl-2018-211540. doi: 10.1136/thoraxjnl-2018-211540.

Pavord ID, Beasley R, Agusti A, et al. The Lancet Commissions. After Asthma: Refining Airways Diseases. Lancet 2017. Published Online September 11, 2017. http://dx.doi.org/10.1016/S0140-6736(17)30879-6

Petsky HL, Kew KM, Turner C, Chang AB. Exhaled nitric oxide levels to guide treatment for adults with asthma. Cochrane Database of Systematic Reviews. 2016, Issue 9. Art. No.: CD011440.

Petsky HL, Kew KM, Chang AB. Exhaled nitric oxide levels to guide treatment for children with asthma. Cochrane Database of Systematic Reviews. 2016, Issue 11. Art. No.: CD011439.

Wang Z, Pianosi P, Keogh K, et al. The Clinical Utility of Fractional Exhaled Nitric Oxide (FeNO) in Asthma Management. Comparative Effectiveness Review No. 197 (Prepared by the Mayo Clinic Evidence-based Practice Center under Contract No. 290-2015-00013-I). AHRQ Publication No.17(18)-EHC030-EF. Rockville, MD: Agency for Healthcare Research and Quality. December 2017. https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/cer-197-fractional-exhaled-nitric-oxide_0.pdf. Accessed January 3, 2018.

Guidelines

GINA-Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA). 2018. Full text available online at: www.ginasthma.org. Accessed on April 10, 2018.

NICE. National Institute for Health and Clinical Excellence. Asthma: diagnosis, monitoring and chronic asthma management NICE guideline [NG80]. November 2017. Available at: https://www.nice.org.uk/guidance/ng80. Accessed February 21, 2018.

Whitepapers

Circassia White Paper. Summary of Evidence Supporting the Clinical Value of Monitoring Exhaled Nitric Oxide (FeNO) in the Management of Asthma. Circassia Pharmaceuticals, Inc. May 2018.

Asthma management is supported by national guidelines that were initially created to emphasize the importance of treating the inflammatory nature of the disease to improve patient outcomes (NHLBI 1991). Today, FeNO (fractional exhaled nitric oxide) is a well-established, validated and specific biomarker for T2 driven airway inflammation in asthma following 20 years since the Nobel Prize was awarded in 1998 for understanding the importance of nitric oxide in the cardiovascular system.